Physician profile
Daniel P Duffy
NPI 1235191511
$194,004.66
in general payments reported to CMS, 2019-2025
36 companies · $74K in 2025
The $74K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $33K · 2021: $13K · 2022: $4,946 · 2023: $11K · 2024: $29K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $43K · Consulting Fee: $33K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Travel and Lodging: $14K · Food and Beverage: $3,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $42,625.00 |
| Consulting Fee | $32,976.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,450.00 |
| Travel and Lodging | $14,211.52 |
| Food and Beverage | $3,340.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $59,797.45 | 2024-2025 | Auvelity |
| Abbvie INC. | $30,728.15 | 2019-2025 | Vraylar |
| Lilly USA, LLC | $29,728.54 | 2019-2025 | Jardiance |
| Eisai INC. | $22,702.23 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $12,935.92 | 2019-2024 | Spravato |
| Allergan, INC. | $9,756.25 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $7,866.86 | 2024-2025 | Caplyta |
| Eli Lilly and Company | $6,901.90 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $4,108.99 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $3,702.93 | 2019-2025 | Rexulti |
| Genentech USA, INC. | $2,124.49 | 2019-2022 | |
| Pfizer INC. | $1,692.70 | 2019-2024 | |
| Astellas Pharma US INC | $387.70 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $329.47 | 2019-2021 | |
| Novo Nordisk INC | $276.92 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $160.02 | 2019 | |
| Amgen INC. | $122.97 | 2019-2025 | Repatha |
| Jazz Pharmaceuticals INC. | $113.98 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.00 | 2019 | |
| Glaxosmithkline, LLC. | $70.95 | 2019 | |
| Boston Scientific Corporation | $60.53 | 2025 | Watchman Access System |
| Bausch Health US, LLC | $47.93 | 2019 | |
| Merck Sharp & Dohme LLC | $36.38 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.40 | 2019 | |
| Sanofi-Aventis U.S. LLC | $32.80 | 2019 | |
| Supernus Pharmaceuticals, INC. | $31.64 | 2024 | Qelbree |
| Ironwood Pharmaceuticals, INC | $28.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.73 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.00 | 2019 | |
| Mylan Specialty L.P. | $16.48 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.87 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.10 | 2019 | |
| Currax Pharmaceuticals LLC | $14.85 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.25 | 2019 | |
| Gilead Sciences, INC. | $13.00 | 2019 | |
| Shire North American Group INC | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Duffy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.